Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy - guidance (TA378)

NICE Accredited

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
27 January 2016

Abstract

Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.

Guidance development process

How we develop NICE technology appraisal guidance

Next review date: January 2019